A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...

Single cell gene expression studies often rely on single-cell RNA sequencing (scRNA-seq) alone. While scRNA-seq reveals which genes are turned on, it does not capture protein expression or changes to ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients. Krystal Biotech, Inc. has announced promising clinical ...

Researchers at the Jackson Laboratory (JAX), the Broad Institute of MIT and Harvard, and Yale University, have used artificial intelligence (AI) to design thousands of new DNA switches that can ...

Advancements in AI, multi-omics, and genome editing are transforming life sciences and biotechnology, addressing new ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...